Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) has a cash flow conversion efficiency ratio of 0.074x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€18.75 Million ≈ $21.91 Million USD) by net assets (€253.42 Million ≈ $296.28 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Eckert & Ziegler Strahlen- und Medizinte (EUZ) defensive interval to measure how many days the company can operate on defensive assets alone.
Eckert & Ziegler Strahlen- und Medizintechnik AG - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Eckert & Ziegler Strahlen- und Medizintechnik AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Eckert & Ziegler Strahlen- und Medizintechnik AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eckert & Ziegler Strahlen- und Medizintechnik AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Banbao Toy Co Ltd
SHG:603398
|
-0.142x |
|
Aeva Technologies, Inc. Common Stock
NYSE:AEVA
|
-0.447x |
|
Sipef NV
BR:SIP
|
0.138x |
|
Suzhou Sunmun Technology Co Ltd
SHE:300522
|
0.052x |
|
Xinjiang Baodi Mining Co. Ltd. A
SHG:601121
|
N/A |
|
Lumexa Imaging Holdings, Inc. Common Stock
NASDAQ:LMRI
|
0.029x |
|
Hongbo Co Ltd
SHE:002229
|
-0.016x |
|
Shanghai Huitong Energy Co Ltd
SHG:600605
|
-0.034x |
Annual Cash Flow Conversion Efficiency for Eckert & Ziegler Strahlen- und Medizintechnik AG (2013–2025)
The table below shows the annual cash flow conversion efficiency of Eckert & Ziegler Strahlen- und Medizintechnik AG from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see EUZ stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €253.42 Million ≈ $296.28 Million |
€58.41 Million ≈ $68.28 Million |
0.230x | -22.03% |
| 2024-12-31 | €225.21 Million ≈ $263.30 Million |
€66.57 Million ≈ $77.83 Million |
0.296x | +39.76% |
| 2023-12-31 | €224.09 Million ≈ $261.99 Million |
€47.40 Million ≈ $55.41 Million |
0.212x | +31.74% |
| 2022-12-31 | €213.63 Million ≈ $249.75 Million |
€34.30 Million ≈ $40.10 Million |
0.161x | -8.70% |
| 2021-12-31 | €192.53 Million ≈ $225.08 Million |
€33.85 Million ≈ $39.58 Million |
0.176x | -25.07% |
| 2020-12-31 | €148.92 Million ≈ $174.10 Million |
€34.95 Million ≈ $40.86 Million |
0.235x | -19.06% |
| 2019-12-31 | €139.44 Million ≈ $163.02 Million |
€40.43 Million ≈ $47.27 Million |
0.290x | +69.34% |
| 2018-12-31 | €123.88 Million ≈ $144.83 Million |
€21.21 Million ≈ $24.80 Million |
0.171x | -25.00% |
| 2017-12-31 | €117.52 Million ≈ $137.39 Million |
€26.83 Million ≈ $31.36 Million |
0.228x | +26.71% |
| 2016-12-31 | €110.08 Million ≈ $128.69 Million |
€19.83 Million ≈ $23.19 Million |
0.180x | +16.19% |
| 2015-12-31 | €104.67 Million ≈ $122.37 Million |
€16.23 Million ≈ $18.97 Million |
0.155x | +37.54% |
| 2014-12-31 | €94.49 Million ≈ $110.47 Million |
€10.65 Million ≈ $12.45 Million |
0.113x | -30.65% |
| 2013-12-31 | €90.27 Million ≈ $105.53 Million |
€14.68 Million ≈ $17.16 Million |
0.163x | -- |
About Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories… Read more